In addition, a multi-antigen targeting strategy has been assessed for multiple myeloma, with anti-BCMA CAR-NK cells engineered with a high-affinity non-cleavable CD16 demonstrating strong efficacy in murine models of myeloma in combination with the anti-CD38 antibody daratumumab [67]. This evidence concerns the gene CD38 and plasma cell myeloma.